Olanzapin
Olanzapine
Film-coated tablets 30 x 5 mg; 30 x 10 mgATC N05A H03
Prescription-only medicine
Reimburse by Health Insurance Fund
POSOLOGY AND METHOD OF ADMINISTRATION
Adults
Elderly: A lower starting dose (5mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant.
Renal and/or hepatic impairment: A lower starting dose (5mg) should be considered for such patients. In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh class A or B), the starting dose should be 5mg and only increased with caution.
Gender: The starting dose and dose range need not be routinely altered for female patients relative to male patients.
Smokers: The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose (5 mg daily). Dose escalation, when indicated, should be conservative in such patients.
Medicine’s information on this web page is only a short description of its characteristics. Do not take them as recommendations for self-treatment of your health condition.
You must inform your physician and pharmacist and follow their recommendations before you use the medicine for treatment. Always read carefully the patient information leaflet.
COMPOSITION
Each film-coated tablet contains 5 mg olanzapine. Each film-coated tablet contains 10 mg olanzapine. |
THERAPEUTIC INDICATIONS
Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to a severe manic episode. At patients with bipolar disorder whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence. |
CONTRAINDICATIONS
Olanzapine is contraindicated at:
– Patients with hypersensitivity to the active substance or to any of the excipients; |
PACKAGING
Box of 30 film-coated tablets of 5 mg (3 blisters x 10 tablets) Box of 30 film-coated tablets of 10 mg (3 blisters x 10 tablets) |
Recent Comments